CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.

Saved in:
Bibliographic Details
Title: CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
Authors: Frank MJ; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Electronic address: mjfrank@stanford.edu., Baird JH; Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA., Kramer AM; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA; Cancer Center Amsterdam, Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Srinagesh HK; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Patel S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Brown AK; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Oak JS; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Younes SF; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Natkunam Y; Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA., Hamilton MP; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Su YJ; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan., Agarwal N; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA., Chinnasamy H; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Egeler E; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Mavroukakis S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Feldman SA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Sahaf B; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Mackall CL; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Muffly L; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA., Miklos DB; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA. Electronic address: dmiklos@stanford.edu.
Corporate Authors: CARdinal-22 Investigator group
Source: Lancet (London, England) [Lancet] 2024 Jul 27; Vol. 404 (10450), pp. 353-363. Date of Electronic Publication: 2024 Jul 09.
Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(24)00746-3